High-Risk Drug Class Audit
NEW August 2023
Section N of the MDS 3.0 v1.18.11 has been significantly changed!
Beginning October 1, 2023, Long-Term Care providers will encode High-Risk Drugs by class – any drugs in those specific classes that were administered to the resident during the 7-day look-back period.
These MDS items require that there is documentation of the indication for each of those high-risk drugs within the resident’s medical record. The physician’s/physician extender’s order must provide that indication. F641 requires that the assessment must accurately reflect the resident’s status.
To prepare for assessment and encoding of Section N, Briggs High-Risk Drug Class Audit is used with each resident that receives any one or more of the drug classes identified as taken during the 7-day look-back period. Included in the audit are these prompts:
• | Identification of the high-risk drug class |
• | Name of the drug |
• | Physician diagnosis or indication for the drug administered |
• | Dosage and frequency |
• | Date drug initiated |
• | Identification of the prescribing physician/physician extender |
• | Location of diagnosis/indication for the use of the drug present within the resident's medical record |
• | Orders for labs pertinent to the administration of the drug as well as monitoring for adverse reactions on the resident-specific care plan |
• | Space for additional notes and comments pertinent to the audit |
Size: 11" x 8 ½"
Paper: White
Print: Black ink, 2-sides different
Punching: 5-holes top and side
Packaging: 100 per pad